Sorrento Therapeutics, Inc.

2023 Q3 Form 10-Q Financial Statement

#000095017023041995 Filed on August 14, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2

Balance Sheet

Concept 2023 Q3 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $80.60M
YoY Change -39.67%
Cash & Equivalents $69.75M
Short-Term Investments $10.90M
Other Short-Term Assets $4.878M
YoY Change -39.57%
Inventory $9.700M
Prepaid Expenses $5.222M
Receivables $32.73M
Other Receivables $0.00
Total Short-Term Assets $133.1M
YoY Change -32.1%
LONG-TERM ASSETS
Property, Plant & Equipment $53.24M
YoY Change 25.18%
Goodwill $80.30M
YoY Change -1.35%
Intangibles $122.3M
YoY Change -29.14%
Long-Term Investments $12.00M
YoY Change -76.35%
Other Assets $2.376M
YoY Change -15.26%
Total Long-Term Assets $323.6M
YoY Change -25.8%
TOTAL ASSETS
Total Short-Term Assets $133.1M
Total Long-Term Assets $323.6M
Total Assets $456.7M
YoY Change -27.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $18.55M
YoY Change -25.6%
Accrued Expenses $91.92M
YoY Change 100.64%
Deferred Revenue $256.0K
YoY Change -74.85%
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $120.4M
YoY Change 407.56%
Total Short-Term Liabilities $264.9M
YoY Change 82.32%
LONG-TERM LIABILITIES
Long-Term Debt $21.74M
YoY Change -73.83%
Other Long-Term Liabilities $3.305M
YoY Change -38.92%
Total Long-Term Liabilities $25.05M
YoY Change -71.69%
TOTAL LIABILITIES
Total Short-Term Liabilities $264.9M
Total Long-Term Liabilities $25.05M
Total Liabilities $654.6M
YoY Change 31.89%
SHAREHOLDERS EQUITY
Retained Earnings -$2.194B
YoY Change 33.3%
Common Stock $2.036B
YoY Change 11.47%
Preferred Stock
YoY Change
Treasury Stock (at cost) $49.46M
YoY Change 0.0%
Treasury Stock Shares
Shareholders Equity -$205.1M
YoY Change
Total Liabilities & Shareholders Equity $456.7M
YoY Change -27.75%

Cashflow Statement

Concept 2023 Q3 2023 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0000850261
dei Amendment Flag
AmendmentFlag
false
CY2023Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q2 us-gaap Accounts Payable Noncurrent Related And Nonrelated Party Status Extensible Enumeration
AccountsPayableNoncurrentRelatedAndNonrelatedPartyStatusExtensibleEnumeration
http://fasb.org/us-gaap/2023#RelatedPartyMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36150
dei Entity Registrant Name
EntityRegistrantName
SORRENTO THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
33-0344842
dei Entity Address Address Line1
EntityAddressAddressLine1
4955 Directors Place
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
203-4100
dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value
dei Trading Symbol
TradingSymbol
SRNEQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
551281154
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
69749000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
23634000
CY2023Q2 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
10886000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
26344000
CY2023Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
32725000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
24469000
CY2023Q2 us-gaap Inventory Net
InventoryNet
9651000
CY2022Q4 us-gaap Inventory Net
InventoryNet
9976000
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5222000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
8807000
CY2023Q2 us-gaap Other Assets Current
OtherAssetsCurrent
4878000
CY2022Q4 us-gaap Other Assets Current
OtherAssetsCurrent
3143000
CY2023Q2 us-gaap Assets Current
AssetsCurrent
133111000
CY2022Q4 us-gaap Goodwill
Goodwill
80269000
CY2023Q2 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
12008000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
96373000
CY2023Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
53237000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
51971000
CY2023Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
53408000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
86464000
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
122283000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
136902000
CY2023Q2 us-gaap Goodwill
Goodwill
80269000
CY2022Q4 us-gaap Equity Securities Fvni Noncurrent
EquitySecuritiesFVNINoncurrent
17176000
CY2023Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2376000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3685000
CY2023Q2 us-gaap Assets
Assets
456692000
CY2022Q4 us-gaap Assets
Assets
472840000
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
18554000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
47515000
CY2023Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6964000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
7884000
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
91924000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
58456000
CY2022Q4 srne Accrued Legal Settlements Current
AccruedLegalSettlementsCurrent
174752000
CY2023Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
256000
CY2022Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
652000
CY2023Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
13051000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
13880000
CY2023Q2 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
397000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
397000
CY2023Q2 us-gaap Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
515000
CY2022Q4 us-gaap Asset Acquisition Contingent Consideration Liability Current
AssetAcquisitionContingentConsiderationLiabilityCurrent
7800000
CY2023Q2 us-gaap Taxes Payable Current
TaxesPayableCurrent
12926000
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
300000
CY2023Q2 us-gaap Long Term Debt Current
LongTermDebtCurrent
120362000
CY2022Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
16286000
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
264949000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
327922000
CY2023Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
21741000
CY2022Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
19130000
CY2023Q2 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
238000
CY2022Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
591000
CY2023Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
896000
CY2022Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
7098000
CY2023Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1600000
CY2022Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
300000
CY2023Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
52446000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
85208000
CY2023Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
550000
CY2022Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
48949000
CY2023Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3305000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5311000
CY2023Q2 srne Liabilities Not Subject To Compromise
LiabilitiesNotSubjectToCompromise
345725000
CY2022Q4 srne Liabilities Not Subject To Compromise
LiabilitiesNotSubjectToCompromise
494509000
CY2023Q2 us-gaap Liabilities Subject To Compromise
LiabilitiesSubjectToCompromise
308923000
CY2023Q2 us-gaap Liabilities
Liabilities
654648000
CY2022Q4 us-gaap Liabilities
Liabilities
494509000
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
750000000
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
551281154
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
551281154
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
522817137
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
522817137
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
55000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
52000
CY2023Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
2036331000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1988753000
CY2023Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
2240000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
1501000
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-2194275000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1959447000
CY2023Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
7568182
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
7568182
CY2023Q2 us-gaap Treasury Stock Value
TreasuryStockValue
49464000
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
49464000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-205113000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-18605000
CY2023Q2 us-gaap Minority Interest
MinorityInterest
7157000
CY2022Q4 us-gaap Minority Interest
MinorityInterest
-3064000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-197956000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-21669000
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
456692000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
472840000
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
15025000
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
11461000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
31276000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
29845000
CY2023Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
33271000
CY2022Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
48467000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
77076000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
112193000
srne Research And Development In Process And Impairment Of Intangible Assets Finite Lived
ResearchAndDevelopmentInProcessAndImpairmentOfIntangibleAssetsFiniteLived
12272000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
48941000
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
48136000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
103920000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
92714000
CY2023Q2 us-gaap Adjustment For Amortization
AdjustmentForAmortization
1127000
CY2022Q2 us-gaap Adjustment For Amortization
AdjustmentForAmortization
1035000
us-gaap Adjustment For Amortization
AdjustmentForAmortization
2254000
us-gaap Adjustment For Amortization
AdjustmentForAmortization
2069000
CY2022Q2 srne Increase Decrease On Contingent Consideration
IncreaseDecreaseOnContingentConsideration
-64300000
srne Increase Decrease On Contingent Consideration
IncreaseDecreaseOnContingentConsideration
3800000
srne Increase Decrease On Contingent Consideration
IncreaseDecreaseOnContingentConsideration
-66400000
CY2023Q2 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
466000
CY2022Q2 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
90780000
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
12366000
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
90780000
us-gaap Legal Fees
LegalFees
1797000
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
92258000
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
129822000
us-gaap Costs And Expenses
CostsAndExpenses
214851000
us-gaap Costs And Expenses
CostsAndExpenses
255089000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-77233000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-118361000
us-gaap Operating Income Loss
OperatingIncomeLoss
-183575000
us-gaap Operating Income Loss
OperatingIncomeLoss
-225244000
CY2023Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-20000
CY2022Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-2700000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1300000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
4800000
CY2023Q2 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-1777000
CY2022Q2 us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-95492000
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-15460000
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-26958000
CY2022Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-471000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-40000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-5732000
CY2023Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
157000
CY2022Q2 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-561000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
153000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-165000
CY2023Q2 us-gaap Interest Expense
InterestExpense
2668000
CY2022Q2 us-gaap Interest Expense
InterestExpense
2314000
us-gaap Interest Expense
InterestExpense
3800000
us-gaap Interest Expense
InterestExpense
5563000
CY2023Q2 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
-4321000
CY2022Q2 us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
-700000
us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
-4299000
us-gaap Nonoperating Gains Losses
NonoperatingGainsLosses
-683000
CY2023Q2 us-gaap Reorganization Items
ReorganizationItems
22003000
us-gaap Reorganization Items
ReorganizationItems
42235000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-107865000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-220599000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-250556000
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-259545000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
671000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1050000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12139000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
413000
CY2022Q2 us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
72000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-368000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-59000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-108536000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-219477000
us-gaap Profit Loss
ProfitLoss
-263063000
us-gaap Profit Loss
ProfitLoss
-260017000
CY2023Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-13324000
CY2022Q2 us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-718000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-28334000
us-gaap Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
-443000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-95212000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-218759000
us-gaap Net Income Loss
NetIncomeLoss
-234729000
us-gaap Net Income Loss
NetIncomeLoss
-259574000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.7
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.7
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
551281000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
402801000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
547232000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
370144000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
551281000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
402801000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
547232000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
370144000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-108536000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-219477000
us-gaap Profit Loss
ProfitLoss
-263063000
us-gaap Profit Loss
ProfitLoss
-260017000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
414000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1060000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
739000
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
837000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
414000
CY2022Q2 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
1060000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
739000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
837000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-108122000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-218417000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-262324000
us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-259180000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-13324000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-718000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-28334000
us-gaap Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
-443000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-94798000
CY2022Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-217699000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-233990000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-258737000
CY2022Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-21669000
CY2023Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
28369000
CY2023Q1 us-gaap Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
18311000
CY2023Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
325000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-154626000
CY2023Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-127420000
CY2023Q2 us-gaap Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
15183000
CY2023Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
414000
CY2023Q2 us-gaap Profit Loss
ProfitLoss
-108536000
CY2023Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
-197956000
CY2021Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
78129000
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
164437000
CY2022Q1 srne Acquisitions Consideration Paid In Equity
AcquisitionsConsiderationPaidInEquity
4435000
CY2022Q1 us-gaap Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
20854000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-1249000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-40540000
CY2022Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
226198000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
104169000
CY2022Q2 us-gaap Stock Granted During Period Value Sharebased Compensation Gross
StockGrantedDuringPeriodValueSharebasedCompensationGross
18369000
CY2022Q2 srne Minority Interest Changes During Period
MinorityInterestChangesDuringPeriod
4776000
CY2022Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
1060000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-219477000
CY2022Q2 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
135763000
us-gaap Profit Loss
ProfitLoss
-263063000
us-gaap Profit Loss
ProfitLoss
-260017000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
7216000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
6534000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
3425000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2176000
us-gaap Paid In Kind Interest
PaidInKindInterest
1179000
us-gaap Paid In Kind Interest
PaidInKindInterest
4892000
srne Payment Notes Attributed To Accreted Interest Related To Debt Discount
PaymentNotesAttributedToAccretedInterestRelatedToDebtDiscount
22057000
srne Acquired In Process Reasearch And Development
AcquiredInProcessReasearchAndDevelopment
12271000
srne Gain Loss On Write Off Of Leasehold Improvements
GainLossOnWriteOffOfLeaseholdImprovements
-386000
us-gaap Share Based Compensation
ShareBasedCompensation
33476000
us-gaap Share Based Compensation
ShareBasedCompensation
39116000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-40000
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-5732000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-1300000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
4800000
us-gaap Gain Loss On Investments
GainLossOnInvestments
-15460000
us-gaap Gain Loss On Investments
GainLossOnInvestments
-26958000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-368000
us-gaap Income Loss From Equity Method Investments
IncomeLossFromEquityMethodInvestments
-59000
us-gaap Inventory Write Down
InventoryWriteDown
2155000
srne Change In Fair Value Of Convertible Notes
ChangeInFairValueOfConvertibleNotes
3748000
srne Debtor In Possession Facility Upfront Lender Fees And Debt Issuance Costs
DebtorInPossessionFacilityUpfrontLenderFeesAndDebtIssuanceCosts
4037000
srne Debtor In Possession Facility Exit Fees
DebtorInPossessionFacilityExitFees
5250000
srne Increase Decrease On Contingent Consideration
IncreaseDecreaseOnContingentConsideration
3800000
srne Increase Decrease On Contingent Consideration
IncreaseDecreaseOnContingentConsideration
-66400000
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
12366000
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
90780000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-353000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-671000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
8256000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
2389000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
1831000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
11375000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-902000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
6989000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-3156000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4280000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
25142000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1427000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
35974000
us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
3976000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
361000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-1587000
srne Increase Decrease In Accrued Legal Settlements
IncreaseDecreaseInAccruedLegalSettlements
1797000
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
12626000
srne Deferred Rent And Other Period Increase Decrease
DeferredRentAndOtherPeriodIncreaseDecrease
-3975000
srne Deferred Rent And Other Period Increase Decrease
DeferredRentAndOtherPeriodIncreaseDecrease
-242000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-105118000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-164348000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
226000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
5298000
us-gaap Proceeds From Sale Of Equity Method Investments
ProceedsFromSaleOfEquityMethodInvestments
1770000
us-gaap Payments To Acquire Businesses Net Of Cash Acquired
PaymentsToAcquireBusinessesNetOfCashAcquired
3550000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1544000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-15392000
srne Proceeds From Debtor In Possession Facility Net Of Lender Fees And Debt Issuance Cost
ProceedsFromDebtorInPossessionFacilityNetOfLenderFeesAndDebtIssuanceCost
70963000
us-gaap Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
6859000
us-gaap Proceeds From Other Short Term Debt
ProceedsFromOtherShortTermDebt
57093000
srne Proceeds From Issuance Of Shares
ProceedsFromIssuanceOfShares
16166000
srne Proceeds From Short Term Convertible Debt
ProceedsFromShortTermConvertibleDebt
24000000
srne Proceeds From Ecapital Revolver
ProceedsFromEcapitalRevolver
17158000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
745000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
805000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
5285000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
111339000
us-gaap Payments Of Merger Related Costs Financing Activities
PaymentsOfMergerRelatedCostsFinancingActivities
1372000
us-gaap Payments Of Dividends
PaymentsOfDividends
11000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
150009000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
215140000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
46435000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
35400000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-320000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1720000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
23634000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
36665000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
69749000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
70345000
us-gaap Interest Paid Net
InterestPaidNet
2228000
us-gaap Interest Paid Net
InterestPaidNet
234000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
28000
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
-31000
srne Professional Fees Paid For Reorganization In Operating Activities
ProfessionalFeesPaidForReorganizationInOperatingActivities
6604000
us-gaap Dividends Stock
DividendsStock
14282000
srne Noncash Or Part Noncash Debtor In Possession Facility Exit Fees Incurred But Not Paid
NoncashOrPartNoncashDebtorInPossessionFacilityExitFeesIncurredButNotPaid
5250000
srne Noncash Or Part Noncash Acquisition Value Of Equity Assumed
NoncashOrPartNoncashAcquisitionValueOfEquityAssumed
4435000
srne Deferred Consideration For Intangible Asset Acquisition
DeferredConsiderationForIntangibleAssetAcquisition
3650000
srne Noncash Or Part Noncash Bridge Loan Settlement Through Atm Proceeds
NoncashOrPartNoncashBridgeLoanSettlementThroughAtmProceeds
6166000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
6388000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
950000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
6.63
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
19748728
CY2023Q3 srne Minimum Sale Of Assets Approved
MinimumSaleOfAssetsApproved
10000000
CY2023Q1 us-gaap Debtor In Possession Financing Amount Arranged
DebtorInPossessionFinancingAmountArranged
75000000
CY2023Q1 srne Debtor In Possession Financing Initial Draw
DebtorInPossessionFinancingInitialDraw
30000000
CY2023Q1 srne Debtor In Possession Financing Access To Remaining Facility
DebtorInPossessionFinancingAccessToRemainingFacility
45000000
srne Debtor In Possession Financing Facility Maturity Date
DebtorInPossessionFinancingFacilityMaturityDate
2023-07-31
CY2023Q2 us-gaap Bankruptcy Claims Last Date To File Claims With Bankruptcy Courts
BankruptcyClaimsLastDateToFileClaimsWithBankruptcyCourts
2023-08-12
CY2023Q2 us-gaap Bankruptcy Claims Number Claims Filed
BankruptcyClaimsNumberClaimsFiled
358
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.02
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
19748728
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
6.02
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">To prepare consolidated financial statements in conformity with accounting principles generally accepted in the U.S., management must make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Customer Concentration Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Scilex Holding had </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">three</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> customers during each of the three and six months ended June 30, 2023,</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> each of which individually generated </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% or more of the Company’s consolidated gross product revenue. These customers accounted for </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">88</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">85</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the Company’s consolidated gross product revenue for the three and six months ended June 30, 2023, respectively, individually ranging from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">24</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% and </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">22</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">32</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%, respectively. As of June 30, 2023, these customers represented </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">81</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% of the Company’s outstanding accounts receivable, individually ranging from </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">21</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">% to </span><span style="font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">30</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">%. Additionally, during each of the three and six months ended June 30, 2023 and 2022, Scilex Holding purchased inventory from its sole supplier, Itochu Chem</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">ical Frontier Corporation. This exposes Scilex Holding to concentration of customer and supplier risk. Scilex Holding monitors the financial condition of its customers, limits its credit exposure by setting credit limits, and has not experienced any credit losses during each of the three and six months ended June 30, 2023 and 2022.</span></p>
CY2023Q2 us-gaap Inventory Net
InventoryNet
9700000
CY2023Q2 us-gaap Inventory Finished Goods
InventoryFinishedGoods
3000000
CY2023Q2 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
6700000
CY2023Q2 us-gaap Debtor In Possession Financing Amount Arranged
DebtorInPossessionFinancingAmountArranged
75000000
CY2023Q3 us-gaap Debtor In Possession Financing Amount Arranged
DebtorInPossessionFinancingAmountArranged
20000000
CY2022Q2 us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
-2700000
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
4800000
CY2023Q2 us-gaap Goodwill
Goodwill
80300000
CY2023Q2 us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
500000
us-gaap Impairment Of Intangible Assets Excluding Goodwill
ImpairmentOfIntangibleAssetsExcludingGoodwill
12400000
CY2023Q2 us-gaap Indefinite Lived Intangible Assets Excluding Goodwill
IndefiniteLivedIntangibleAssetsExcludingGoodwill
81900000
CY2023Q2 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
148365000
CY2023Q2 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
26082000
CY2023Q2 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
122283000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
160731000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
23829000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
136902000
CY2023Q2 us-gaap Adjustment For Amortization
AdjustmentForAmortization
1100000
CY2022Q2 us-gaap Adjustment For Amortization
AdjustmentForAmortization
1000000
us-gaap Adjustment For Amortization
AdjustmentForAmortization
2300000
us-gaap Adjustment For Amortization
AdjustmentForAmortization
2100000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
13219000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
12878000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
2162000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
4239000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
4214000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
4214000
CY2023Q2 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
4187000
CY2023Q2 srne Finite Lived Intangible Assets Amortization Expense After Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFour
21393000
CY2023Q2 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
40409000
CY2023Q2 srne Sales And Regulatory Milestone Payments
SalesAndRegulatoryMilestonePayments
0
CY2023Q2 us-gaap Interest Expense Debt
InterestExpenseDebt
1900000
us-gaap Interest Expense Debt
InterestExpenseDebt
2200000
CY2023Q2 us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.14
us-gaap Debt Instrument Interest Rate During Period
DebtInstrumentInterestRateDuringPeriod
0.14
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
20861760
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
6.05
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1113032
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
8284498
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
3.73
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
1381951
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
4.23
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
6902547
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
3.63
CY2023Q1 srne Antibody Award Judgment Exceeds Offset
AntibodyAwardJudgmentExceedsOffset
50000000
CY2023Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
4089000
CY2022Q2 us-gaap Operating Lease Payments
OperatingLeasePayments
3422000
us-gaap Operating Lease Payments
OperatingLeasePayments
7991000
us-gaap Operating Lease Payments
OperatingLeasePayments
6304000
CY2023Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2680000
CY2022Q2 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2328000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2680000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
2961000
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y8M12D
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P14Y4M24D
CY2023Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P6Y8M12D
CY2022Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P14Y4M24D
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.127
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.128
CY2023Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.127
CY2022Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.128
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
7114000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
14152000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
13052000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
13380000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
23991000
CY2023Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
97786000
CY2023Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
32289000
CY2023Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
65497000
CY2023Q2 srne Decrease In Right Of Use Assets And Liabilities Due To Remeasurement
DecreaseInRightOfUseAssetsAndLiabilitiesDueToRemeasurement
25800000
CY2023Q2 srne Decrease In Right Of Use Assets And Liabilities Due To Remeasurement
DecreaseInRightOfUseAssetsAndLiabilitiesDueToRemeasurement
25800000
CY2023Q2 srne Deferred Income Tax Liability Stock Dividend
DeferredIncomeTaxLiabilityStockDividend
12700000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
12100000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
400000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.048
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.002
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
700000
CY2022Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1100000
CY2023Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.007
CY2022Q2 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.005
us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.048
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-95212000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-218759000
us-gaap Net Income Loss
NetIncomeLoss
-234729000
us-gaap Net Income Loss
NetIncomeLoss
-259574000
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-95212000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-218759000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-234729000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-259574000
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
551281000
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
402801000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
547232000
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
370144000
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
551281000
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
402801000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
547232000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
370144000
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.54
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.43
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.7
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.54
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.43
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.7
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
26585000
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
24065000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27656000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
23177000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
2
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
15025000
CY2022Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
11461000
CY2023Q2 us-gaap Costs And Expenses
CostsAndExpenses
92258000
CY2022Q2 us-gaap Costs And Expenses
CostsAndExpenses
129822000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-77233000
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-118361000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
69749000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70345000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
31276000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
29845000
us-gaap Costs And Expenses
CostsAndExpenses
214851000
us-gaap Costs And Expenses
CostsAndExpenses
255089000
us-gaap Operating Income Loss
OperatingIncomeLoss
-183575000
us-gaap Operating Income Loss
OperatingIncomeLoss
-225244000
CY2023Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
69749000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
70345000
CY2023Q2 us-gaap Accounts Payable Interest Bearing Noncurrent
AccountsPayableInterestBearingNoncurrent
56078000
CY2023Q2 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
7839000
CY2023Q2 srne Liabilities Subject To Compromise Accrued Legal Settlements
LiabilitiesSubjectToCompromiseAccruedLegalSettlements
176549000
CY2023Q2 srne Liabilities Subject To Compromise Current Portion Of Contingent Consideration
LiabilitiesSubjectToCompromiseCurrentPortionOfContingentConsideration
6959000
CY2023Q2 srne Liabilities Subject To Compromise Long Term Portion Of Contingent Considerations And Acquisition Consideration
LiabilitiesSubjectToCompromiseLongTermPortionOfContingentConsiderationsAndAcquisitionConsideration
61498000
CY2023Q2 us-gaap Accounts Payable And Accrued Liabilities Noncurrent
AccountsPayableAndAccruedLiabilitiesNoncurrent
308923000
CY2023Q2 us-gaap Debtor Reorganization Items Debtor In Possession Facility Financing Costs
DebtorReorganizationItemsDebtorInPossessionFacilityFinancingCosts
1468000
CY2022Q2 us-gaap Debtor Reorganization Items Debtor In Possession Facility Financing Costs
DebtorReorganizationItemsDebtorInPossessionFacilityFinancingCosts
0
us-gaap Debtor Reorganization Items Debtor In Possession Facility Financing Costs
DebtorReorganizationItemsDebtorInPossessionFacilityFinancingCosts
4229000
us-gaap Debtor Reorganization Items Debtor In Possession Facility Financing Costs
DebtorReorganizationItemsDebtorInPossessionFacilityFinancingCosts
0
CY2023Q2 srne Debtor In Possession Facility Exit Fees
DebtorInPossessionFacilityExitFees
0
CY2022Q2 srne Debtor In Possession Facility Exit Fees
DebtorInPossessionFacilityExitFees
0
srne Debtor In Possession Facility Exit Fees
DebtorInPossessionFacilityExitFees
5250000
srne Debtor In Possession Facility Exit Fees
DebtorInPossessionFacilityExitFees
0
CY2023Q2 srne Reorganization Professional Fees
ReorganizationProfessionalFees
15565000
CY2022Q2 srne Reorganization Professional Fees
ReorganizationProfessionalFees
0
srne Reorganization Professional Fees
ReorganizationProfessionalFees
27786000
srne Reorganization Professional Fees
ReorganizationProfessionalFees
0
CY2023Q2 srne Reorganization Lease Termination
ReorganizationLeaseTermination
4195000
CY2022Q2 srne Reorganization Lease Termination
ReorganizationLeaseTermination
0
srne Reorganization Lease Termination
ReorganizationLeaseTermination
4195000
srne Reorganization Lease Termination
ReorganizationLeaseTermination
0
CY2023Q2 srne Reorganization Others Fees
ReorganizationOthersFees
775000
CY2022Q2 srne Reorganization Others Fees
ReorganizationOthersFees
0
srne Reorganization Others Fees
ReorganizationOthersFees
775000
srne Reorganization Others Fees
ReorganizationOthersFees
0
CY2023Q2 us-gaap Reorganization Items
ReorganizationItems
22003000
CY2022Q2 us-gaap Reorganization Items
ReorganizationItems
0
us-gaap Reorganization Items
ReorganizationItems
42235000
us-gaap Reorganization Items
ReorganizationItems
0
ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-23-041995-index-headers.html Edgar Link pending
0000950170-23-041995-index.html Edgar Link pending
0000950170-23-041995.txt Edgar Link pending
0000950170-23-041995-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
srne-20230630.htm Edgar Link pending
srne-20230630.xsd Edgar Link pending
srne-ex31_1.htm Edgar Link pending
srne-ex31_2.htm Edgar Link pending
srne-ex32_1.htm Edgar Link pending
srne-20230630_cal.xml Edgar Link unprocessable
srne-20230630_def.xml Edgar Link unprocessable
srne-20230630_lab.xml Edgar Link unprocessable
srne-20230630_pre.xml Edgar Link unprocessable
srne-20230630_htm.xml Edgar Link completed